<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39575583</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>22</Day></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Neurologic Manifestations of Long COVID Disproportionately Affect Young and Middle-Age Adults.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.27128</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate neurologic manifestations of post-acute sequelae of SARS-CoV-2 infection (Neuro-PASC) in post-hospitalization Neuro-PASC (PNP) and non-hospitalized Neuro-PASC (NNP) patients across the adult lifespan.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Cross-sectional study of the first consecutive 200 PNP and 1,100 NNP patients evaluated at a Neuro-coronavirus disease 2019 (COVID-19) clinic between May 2020 and March 2023. Patients were divided into younger (18-44&#x2009;years), middle-age (45-64&#x2009;years), and older (65+ years) age groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Younger and middle-age individuals accounted for 142 of 200 (71%) of PNP and 995 of 1100 (90.5%) of NNP patients. Significant age-related differences in the frequencies of comorbidities and abnormal neurologic findings demonstrated higher prevalence in older patients. Conversely, 10&#x2009;months from COVID-19 onset, we found significant age-related differences in Neuro-PASC symptoms indicating lower prevalence, and therefore, symptom burden, in older individuals. Moreover, there were significant age-related differences in subjective impression of fatigue (median [interquartile range (IQR)] patient-reported outcomes measurement information system [PROMIS] score: younger 64 [57-69], middle-age 63 [57-68], older 60.5 [50.8-68.3]; p&#x2009;=&#x2009;0.04) and sleep disturbance (median [IQR] PROMIS score: younger 57 [51-63], middle-age 56 [53-63], older 54 [46.8-58]; p&#x2009;=&#x2009;0.002) in the NNP group, commensurate with higher impairment in quality of life (QoL) among younger patients. Finally, there were significant age-related differences in objective executive function (median [IQR] National Institutes of Health [NIH] toolbox score: younger 48 [35-63], middle-age 49 [38-63], older 54.5 [45-66.3]; p&#x2009;=&#x2009;0.01), and working memory (median [IQR] NIH toolbox score: younger 47 [40-53], middle-age 50 [44-57], older 48 [43-58]; p&#x2009;=&#x2009;0.0002) in NNP patients, with the worst performance coming from the younger group.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Younger and middle-age individuals are disproportionally affected by Neuro-PASC regardless of acute COVID-19 severity. Although older people more frequently have abnormal neurologic findings and comorbidities, younger and middle-age patients suffer from a higher burden of Neuro-PASC symptoms and cognitive dysfunction contributing to decreased QoL. Neuro-PASC principally affects adults in their prime, contributing to profound public health and socioeconomic impacts warranting dedicated resources for prevention, diagnosis and interventions. ANN NEUROL 2024.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choudhury</LastName><ForeName>Natasha A</ForeName><Initials>NA</Initials><Identifier Source="ORCID">0000-0002-4321-7344</Identifier><AffiliationInfo><Affiliation>Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Mukherjee</LastName><ForeName>Shreya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Singer</LastName><ForeName>Tracey</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Venkatesh</LastName><ForeName>Aditi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perez Giraldo</LastName><ForeName>Gina S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jimenez</LastName><ForeName>Millenia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Janet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanson</LastName><ForeName>Barbara A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bawa</LastName><ForeName>Aasheeta P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Northwestern Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Batra</LastName><ForeName>Ayush</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4783-5801</Identifier><AffiliationInfo><Affiliation>Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liotta</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0003-3182-585X</Identifier><AffiliationInfo><Affiliation>Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koralnik</LastName><ForeName>Igor J</ForeName><Initials>IJ</Initials><Identifier Source="ORCID">0000-0001-6836-1468</Identifier><AffiliationInfo><Affiliation>Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23AG078705 to EML</GrantID><Agency>NIH/NIA</Agency><Country/></Grant><Grant><GrantID>R21AG086751 to AB</GrantID><Agency>NIH/NIA</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>5</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39575583</ArticleId><ArticleId IdType="doi">10.1002/ana.27128</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>World Health Organization (WHO). Coronavirus (COVID&#x2010;19) Dashboard, Available at: https://covid19.who.int/.</Citation></Reference><Reference><Citation>O'Mahoney LL, Routen A, Gillies C, et al. The prevalence and long&#x2010;term health effects of long Covid among hospitalised and non&#x2010;hospitalised populations: a systematic review and meta&#x2010;analysis. EClinicalMedicine 2023;55:101762.</Citation></Reference><Reference><Citation>Global Burden of Disease Long CC, Wulf Hanson S, Abbafati C, et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID&#x2010;19 in 2020 and 2021. JAMA 2022;328:1604&#x2013;1615.</Citation></Reference><Reference><Citation>Long COVID basics. Centers for Disease Control and Prevention Available at: https://www.cdc.gov/covid/long-term-effects/?.</Citation></Reference><Reference><Citation>WHO COVID&#x2010;19 Case definition, 2020. Available at: https://apps.who.int/iris/handle/10665/337834 https://www.who.int/publications/i/item/WHO-2019-nCoV-Surveillance_Case_Definition-2020.2.</Citation></Reference><Reference><Citation>Collaborators GBDNSD. Global, regional, and national burden of disorders affecting the nervous system, 1990&#x2013;2021: a systematic analysis for the global burden of disease study 2021. Lancet Neurol 2024;23:344&#x2013;381.</Citation></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long COVID in non&#x2010;hospitalized adults. Nat Med 2022;28:1706&#x2013;1714.</Citation></Reference><Reference><Citation>Bailey J, Lavelle B, Miller J, et al. Multidisciplinary Center Care for Long COVID syndrome &#x2010; a retrospective cohort study. Am J Med 2023.</Citation></Reference><Reference><Citation>Perez Giraldo GS, Ali ST, Kang AK, et al. Neurologic manifestations of long COVID differ based on acute COVID&#x2010;19 severity. Ann Neurol 2023;94:146&#x2013;159.</Citation></Reference><Reference><Citation>Brus IM, Spronk I, Haagsma JA, et al. The prolonged impact of COVID&#x2010;19 on symptoms, health&#x2010;related quality of life, fatigue and mental well&#x2010;being: a cross&#x2010;sectional study. Front Epidemiol 2023;3:1144707.</Citation></Reference><Reference><Citation>Xu E, Xie Y, Al&#x2010;Aly Z. Long&#x2010;term neurologic outcomes of COVID&#x2010;19. Nat Med 2022;28:2406&#x2013;2415.</Citation></Reference><Reference><Citation>Di Fusco M, Cappelleri JC, Anatale&#x2010;Tardiff L, et al. Impact of COVID&#x2010;19 infection on health&#x2010;related quality of life, work productivity and activity impairment by symptom&#x2010;based long COVID status and age in the US. Healthcare (Basel) 2023;11:2790.</Citation></Reference><Reference><Citation>Tanguay P, Decary S, Lemaire&#x2010;Paquette S, et al. Trajectories of health&#x2010;related quality of life and their predictors in adult COVID&#x2010;19 survivors: a longitudinal analysis of the Biobanque Quebecoise de la COVID&#x2010;19 (BQC&#x2010;19). Qual Life Res 2023;32:2707&#x2013;2717.</Citation></Reference><Reference><Citation>Bai F, Tomasoni D, Falcinella C, et al. Female gender is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect 2022;28:611.e9&#x2013;e616.e9.</Citation></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med 2021;27:626&#x2013;631.</Citation></Reference><Reference><Citation>Taquet M, Sillett R, Zhu L, et al. Neurological and psychiatric risk trajectories after SARS&#x2010;CoV&#x2010;2 infection: an analysis of 2&#x2010;year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry 2022;9:815&#x2013;827.</Citation></Reference><Reference><Citation>Perlis RH, Santillana M, Ognyanova K, et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open 2022;5:e2238804.</Citation></Reference><Reference><Citation>Liotta EM, Batra A, Clark JR, et al. Frequent neurologic manifestations and encephalopathy&#x2010;associated morbidity in Covid&#x2010;19 patients. Ann Clin Transl Neurol 2020;7:2221&#x2013;2230.</Citation></Reference><Reference><Citation>Frontera JA, Sabadia S, Lalchan R, et al. A prospective study of neurologic disorders in hospitalized patients with COVID&#x2010;19 in new York City. Neurology 2021;96:e575&#x2013;e586.</Citation></Reference><Reference><Citation>Lai JS, Cella D, Choi S, et al. How item banks and their application can influence measurement practice in rehabilitation medicine: a PROMIS fatigue item bank example. Arch Phys Med Rehabil 2011;92:S20&#x2013;S27.</Citation></Reference><Reference><Citation>Lai JS, Wagner LI, Jacobsen PB, Cella D. Self&#x2010;reported cognitive concerns and abilities: two sides of one coin? Psychooncology 2014;23:1133&#x2013;1141.</Citation></Reference><Reference><Citation>Gershon RC, Cella D, Fox NA, et al. Assessment of neurological and behavioural function: the NIH toolbox. Lancet Neurol 2010;9:138&#x2013;139.</Citation></Reference><Reference><Citation>Gershon RC, Wagster MV, Hendrie HC, et al. NIH toolbox for assessment of neurological and behavioral function. Neurology 2013;80:S2&#x2013;S6.</Citation></Reference><Reference><Citation>Weintraub S, Dikmen SS, Heaton RK, et al. Cognition assessment using the NIH toolbox. Neurology 2013;80:S54&#x2013;S64.</Citation></Reference><Reference><Citation>Heaton RK, Akshoomoff N, Tulsky D, et al. Reliability and validity of composite scores from the NIH toolbox cognition battery in adults. J Int Neuropsychol Soc 2014;20:588&#x2013;598.</Citation></Reference><Reference><Citation>Heightman M, Prashar J, Hillman TE, et al. Post&#x2010;COVID&#x2010;19 assessment in a specialist clinical service: a 12&#x2010;month, single&#x2010;centre, prospective study in 1325 individuals. BMJ Open Respir Res 2021;8:e001041.</Citation></Reference><Reference><Citation>Peghin M, Palese A, Venturini M, et al. Post&#x2010;COVID&#x2010;19 symptoms 6 months after acute infection among hospitalized and non&#x2010;hospitalized patients. Clin Microbiol Infect 2021;27:1507&#x2013;1513.</Citation></Reference><Reference><Citation>Perez&#x2010;Gonzalez A, Araujo&#x2010;Ameijeiras A, Fernandez&#x2010;Villar A, et al. Long COVID in hospitalized and non&#x2010;hospitalized patients in a large cohort in Northwest Spain, a prospective cohort study. Sci Rep 2022;12:3369.</Citation></Reference><Reference><Citation>Russell SJ, Parker K, Lehoczki A, et al. Post&#x2010;acute sequelae of SARS&#x2010;CoV&#x2010;2 infection (long COVID) in older adults. Geroscience 2024;46:6563&#x2013;6581.</Citation></Reference><Reference><Citation>Iosifescu AL, Hoogenboom WS, Buczek AJ, et al. New&#x2010;onset and persistent neurological and psychiatric sequelae of COVID&#x2010;19 compared to influenza: a retrospective cohort study in a large new York City healthcare network. Int J Methods Psychiatr Res 2022;31:e1914.</Citation></Reference><Reference><Citation>Thaweethai T, Jolley SE, Karlson EW, et al. Development of a definition of Postacute sequelae of SARS&#x2010;CoV&#x2010;2 infection. JAMA 2023;329:1934&#x2013;1946.</Citation></Reference><Reference><Citation>Batra A, Nath A, Koralnik IJ. Postacute sequelae of SARS&#x2010;CoV&#x2010;2 infection. JAMA 2023;330:1491&#x2013;1492.</Citation></Reference><Reference><Citation>Gross R, Lo Re V. Disentangling the Postacute sequelae of SARS&#x2010;CoV&#x2010;2: E Unibus Pluram (from one, many). JAMA 2023;329:1918&#x2013;1919.</Citation></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021;38:101019.</Citation></Reference><Reference><Citation>Long COVID Household Pulse Survey. National Center for Health Statistic &amp; US Census Bureau, Available at: https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm.</Citation></Reference><Reference><Citation>Zarifkar P, Peinkhofer C, Benros ME, Kondziella D. Frequency of neurological diseases after COVID&#x2010;19, influenza a/B and bacterial pneumonia. Front Neurol 2022;13:904796.</Citation></Reference><Reference><Citation>Rahmati M, Yon DK, Lee SW, et al. New&#x2010;onset neurodegenerative diseases as long&#x2010;term sequelae of SARS&#x2010;CoV&#x2010;2 infection: a systematic review and meta&#x2010;analysis. J Med Virol 2023;95:e28909.</Citation></Reference><Reference><Citation>Zhao J, Xia F, Jiao X, Lyu X. Long COVID and its association with neurodegenerative diseases: pathogenesis, neuroimaging, and treatment. Front Neurol 2024;15:1367974.</Citation></Reference><Reference><Citation>Huang P, Zhang LY, Tan YY, Chen SD. Links between COVID&#x2010;19 and Parkinson's disease/Alzheimer's disease: reciprocal impacts, medical care strategies and underlying mechanisms. Transl Neurodegener 2023;12:5.</Citation></Reference><Reference><Citation>McElvaney OJ, McEvoy NL, McElvaney OF, et al. Characterization of the inflammatory response to severe COVID&#x2010;19 illness. Am J Respir Crit Care Med 2020;202:812&#x2013;821.</Citation></Reference><Reference><Citation>Xie C, Li Q, Li L, et al. Association of Early Inflammation with age and asymptomatic disease in COVID&#x2010;19. J Inflamm Res 2021;14:1207&#x2013;1216.</Citation></Reference><Reference><Citation>Gordon MN, Heneka MT, Le Page LM, et al. Impact of COVID&#x2010;19 on the onset and progression of Alzheimer's disease and related dementias: a roadmap for future research. Alzheimers Dement 2022;18:1038&#x2013;1046.</Citation></Reference><Reference><Citation>Boura I, Qamar MA, Daddoveri F, et al. SARS&#x2010;CoV&#x2010;2 and Parkinson's disease: a review of where we are now. Biomedicine 2023;11:2524.</Citation></Reference><Reference><Citation>Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990;1:43&#x2013;46.</Citation></Reference><Reference><Citation>Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998;316:1236&#x2013;1238.</Citation></Reference><Reference><Citation>Erlandson KM, Geng LN, Selvaggi CA, et al. Differentiation of prior SARS&#x2010;CoV&#x2010;2 infection and Postacute sequelae by standard clinical laboratory measurements in the RECOVER cohort. Ann Intern Med 2024;177:1209&#x2013;1221.</Citation></Reference><Reference><Citation>Harrison JM, Ernecoff NC, Lai JS, et al. Health system implementation of the PROMIS cognitive function screener in the Medicare annual wellness visit: framing as abilities versus concerns. J Patient Rep Outcomes 2024;8:43.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>